Elixirgen Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines.

About Elixirgen Therapeutics

Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company co-founded by Akihiro Ko and Minoru Ko, MD, PhD in 2017. The company is focused on curing humanity’s ailments through innovations in stem cell biology. The company’s experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics' scientists to conduct research at state-of-the-art facilities.

About Location
About Location
Akihiro Ko

AKIHIRO KO

Chief Executive Officer

AKIHIRO KO

Chief Executive Officer

Akihiro Ko has served as Chief Executive Officer and as a member of the board of directors since May 2017 and was a co-founder of the company with Minoru Ko. Previously, Mr. Ko served as Chief Operating Officer for Elixirgen, LLC, the parent company of Elixirgen Therapeutics, and President of Elixirgen Scientific, LLC, a provider of stem cell reagent kits and related services. In his previous roles, Mr. Ko was responsible for business operations, marketing, and business development at Elixirgen, LLC and Elixirgen Scientific. Mr. Ko earned a Bachelor of Science degree from University of Virginia, where he cultivated his interest in stem cell biology and epigenetics through his research involving bivalent domains in cancer stem cells.

Minoru Ko

MINORU KO, MD, PhD

Chief Scientific Officer

MINORU KO, MD, PhD

Chief Scientific Officer

Minoru S.H. Ko, MD, PhD has served as Chief Scientific Officer and as a member of the board of directors since May 2017 and was a co-founder of the company with Akihiro Ko. In addition, Dr. Ko is currently Professor and Chair at the Department of Systems Medicine, Keio University School of Medicine. In 2012, Dr. Ko founded Elixirgen, LLC to develop novel products based on stem cell related technology. In 2016, Dr. Ko founded Elixirgen Scientific, LLC. Prior to forming Elixirgen, LLC, Dr. Ko worked as Senior Investigator (tenured) and Section Chief at the National Institute on Aging, a division of the National Institutes of Health. He also previously served as Assistant Professor and Associate Professor (Tenured) at Wayne State University School of Medicine. Dr. Ko has published more than 150 peer-reviewed scientific articles and more than 20 other articles and book chapters, including a “Stem Cell Biology” chapter of Harrison’s Principles of Internal Medicine (17th, 18th, 19th editions). Dr. Ko brings more than 30 years of experience in stem cell biology, genetics, molecular and cell biology, and systems biology.

Joel Rogers

JOEL ROGERS, CPA

Chief Financial Officer

JOEL ROGERS, CPA

Chief Financial Officer

Joel D. Rogers, CPA has served as Chief Financial Officer since December 2019. Mr. Rogers previously worked at Osiris Therapeutics, Inc. (NASDAQ: OSIR), which was acquired by Smith & Nephew in April 2019, as Chief Financial Officer from May 2018 to October 2019 and Corporate Controller from October 2017 to May 2018. Mr. Rogers served as Corporate Controller at ARC Group Worldwide, Inc. (NASDAQ: ARCW) from August 2014 to October 2017. Prior to ARC Group Worldwide, Inc., Mr. Rogers served in accounting management roles at DigitalGlobe, Inc. (NYSE: DGI), Allos Therapeutics, Inc. (NASDAQ: ALTH), and Flex LTD. (NASDAQ: FLEX). Mr. Rogers began his career as an auditor at Deloitte & Touche LLP. He holds a Bachelor of Arts (Accounting) from the University of Washington and a Master of Business Administration from Cornell University. He is a Certified Public Accountant (Colorado).

Yosuke Tochihara

YOSUKE TOCHIHARA

Chief Accounting Officer

YOSUKE TOCHIHARA

Chief Accounting Officer

Yosuke Tochihara, CPA has served as Chief Accounting Officer since August 2019. From October 2013 to July 2019, Mr. Tochihara worked as a Manager and various other roles in risk advisory services at Deloitte & Touche Tohmatsu. From December 2006 to September 2013, Mr. Tochihara worked as an auditor at PwC. Mr. Tochihara began his career as a salesperson at Yamanouchi Pharma (Currently Astellas Pharma). He is a Certified Public Accountant (Japan).

Akihiro Ko

AKIHIRO KO

Board Member

AKIHIRO KO

Board Member

Akihiro Ko has served as Chief Executive Officer and as a member of the board of directors since May 2017 and was a co-founder of the company with Minoru Ko. Previously, Mr. Ko served as Chief Operating Officer for Elixirgen, LLC, the parent company of Elixirgen Therapeutics, and President of Elixirgen Scientific, LLC, a provider of stem cell reagent kits and related services. In his previous roles, Mr. Ko was responsible for business operations, marketing, and business development at Elixirgen, LLC and Elixirgen Scientific. Mr. Ko earned a Bachelor of Science degree from University of Virginia, where he cultivated his interest in stem cell biology and epigenetics through his research involving bivalent domains in cancer stem cells.

Minoru Ko

MINORU KO, MD, PhD

Board Member

MINORU KO, MD, PhD

Board Member

Minoru S.H. Ko, MD, PhD has served as Chief Scientific Officer and as a member of the board of directors since May 2017 and was a co-founder of the company with Akihiro Ko. In addition, Dr. Ko is currently Professor and Chair at the Department of Systems Medicine, Keio University School of Medicine. In 2012, Dr. Ko founded Elixirgen, LLC to develop novel products based on stem cell related technology. In 2016, Dr. Ko founded Elixirgen Scientific, LLC. Prior to forming Elixirgen, LLC, Dr. Ko worked as Senior Investigator (tenured) and Section Chief at the National Institute on Aging, a division of the National Institutes of Health. He also previously served as Assistant Professor and Associate Professor (Tenured) at Wayne State University School of Medicine. Dr. Ko has published more than 150 peer-reviewed scientific articles and more than 20 other articles and book chapters, including a “Stem Cell Biology” chapter of Harrison’s Principles of Internal Medicine (17th, 18th, 19th editions). Dr. Ko brings more than 30 years of experience in stem cell biology, genetics, molecular and cell biology, and systems biology.

Naonori Kurokawa

NAONORI KUROKAWA, PhD

Board Member

NAONORI KUROKAWA, PhD

Board Member

Naonori Kurokawa, PhD, has served as a director of the company since November 2018. Dr. Kurokawa currently serves as a Partner at University of Tokyo Edge Capital Company (UTEC) He focuses on physical science and life science investments, including advanced material, nanotechnology, optoelectronics, imaging technology, life science tools, diagnostics, medical devices, and therapeutics. He has been taking key roles in the investment of Microwave Chemical, 908 Devices, FLOSFIA, Quantum Biosystems, MOLCURE, Immunoscape and Elixirgen Therapeutics. Mr. Kurokaw received his MBA at the University of Chicago Booth School of Business where he won the first place and the award for the most innovative plan in Edward L. Kaplan New Venture Challenge 2008. He earned his Ph.D. in applied physics from Osaka University in 2003.

Hiroaki Kobayashi

HIROAKI KOBAYASHI, MD

Board Member

HIROAKI KOBAYASHI, MD

Board Member

Hiroaki Kobayashi, MD, has served as a director of the company since February 2020. Dr. Kobayashi currently serves as a Venture Partner at University of Tokyo Edge Capital Company (UTEC), focusing on supporting companies in the life sciences and medical fields. Prior to UTEC, Dr. Kobayashi worked for several medical device companies, including an early-stage start-up. He is an emergency medicine and intensive care physician by training, and worked 5+ years in multiple academic medical centers. As a Fulbright scholar, he received an MBA with distinction at the Ross School of Business at the University of Michigan, where he focused on strategy and healthcare management. He earned his M.D. from the University of Tokyo.

Thomas White

THOMAS J. WHITE, PhD

Board Member

THOMAS J. WHITE, PhD

Board Member

Thomas J. White, PhD has served as a director for the company since March 2020.  From 2001-2011, Dr. White served as Senior Vice President of Research and Development and Chief Scientific Officer at Celera Corporation.  His research at Celera involved the discovery of new genomic, expression and proteomic biomarkers and the development and FDA registration of molecular diagnostic products for cystic fibrosis, Fragile-X, HIV drug resistance, hepatitis C virus genotyping, thrombosis, as well as laboratory developed (CLIA) tests for complex common diseases (cardiovascular, stroke, autoimmunity, liver) and breast cancer.  From 1989-2000, Dr. White worked as Senior Vice President of R&D for Roche Molecular Systems, a diagnostics division of Hoffmann-La Roche.  From 1978-1988, Dr. White was employed at the biotechnology firm Cetus Corporation where he held the positions of Senior Vice President of Research and Associate Director of Research and Development.  Dr. White received his B.A. in Chemistry from Johns Hopkins University and a Ph.D. in Biochemistry from the University of California at Berkeley, including graduate studies in the Pharmacology Department at the Johns Hopkins School of Medicine. 

Shauna Calalahan

SHAUNA CALLAHAN, CPA

Board Member

SHAUNA CALLAHAN, CPA

Board Member

Shauna Callahan, CPA has served as a director for the company since March 2020.  From 2019 to present, Ms. Callahan serves as the Chief Financial Officer for CampMinder, LLC.  Ms. Callahan also serves as a director for Anchor Center for Blind Children.  Her experience has centered around providing financial expertise and diligence to mid-sized businesses navigating high growth both organically and by acquisition.  Ms. Callahan started her career in public accounting at Arthur Andersen in Denver, Colorado subsequently holding financial roles in a variety of public and private companies in industries including market research, telecommunications, distribution, and manufacturing.  She graduated Summa Cum Laude from the University of Colorado with a Bachelor of Science in Business Administration and Accounting.

Stephen M Feinstone

STEPHEN M. FEINSTONE, MD

STEPHEN M. FEINSTONE, MD

Stephen M. Feinstone, MD, served from 2012 until his recent retirement as adjunct professor in the Department of Biochemistry and Molecular Medicine at George Washington University. Prior to that, Dr. Feinstone worked as Chief at the Laboratory of Hepatitis Viruses, Division of Viral Products at the Center for Biologics Research and Review (CBER), a branch of the U.S. Food and Drug Administration (FDA). Dr. Feinstone also worked as Senior Investigator in the Laboratory of Infectious Diseases. In these roles, Dr. Feinstone’s work along with that of collaborators, identified the virus that caused hepatitis type A and led to the development of the first licensed hepatitis A vaccine, HAVRIX. Further research led to the discovery of hepatitis C, and his more recent research focused on the virology and immunopathogenesis of hepatitis C virus infections and applying this information to experimental vaccine development. Dr. Feinstone received his undergraduate education at the Johns Hopkins University and his medical degree from the University of Tennessee. He did his clinical training at the Medical College of Wisconsin in Milwaukee and at Georgetown University Hospital and the Washington Veterans Administration Hospital in Washington, DC.

David Schlessinger

DAVID SCHLESSINGER, PhD

DAVID SCHLESSINGER, PhD

David Schlessinger, Ph.D., is currently National Institutes of Health Distinguished Investigator Emeritus and a Volunteer and Advisor to the Sardinian population study in the Laboratory of Genetics and Genomics, which he founded at the National Institute on Aging (NIA) in 1997. Previous to NIA, Dr. Schlessinger was Professor of Molecular Microbiology, Genetics, and Microbiology in Medicine at Washington University in St. Louis. He has trained more than 300 Fellows, many of whom have taken on leadership positions around the world. The scope of his interests in over 600 publications range from the action of antibiotics and the formation of ribosomes to the genetics of developmental and aging-related human traits and disease susceptibility. Dr. Schlessinger received his doctoral degree from Harvard University.

Shinichiro Okamoto

Shinichiro Okamoto, MD, PhD

Shinichiro Okamoto, MD, PhD

Shinichiro Okamoto, MD, PhD, graduated from the School of Medicine at Keio University in 1979 and received a PhD from Keio University in 1983. From 1985 to 1988, Dr. Okamoto worked as a research/clinical fellow at the Division of Hematology/Oncology, Emory University in Atlanta, and as a visiting clinical fellow at the Fred Hutchinson Cancer Research Center in Seattle. After his training in the U.S., He came back to Keio University, and has continued to work in the field of hematopoietic cell transplantation until now. He is current the Chairman and Professor of Medicine, Department of Medicine at Keio University, and the Director of Hematology Service at Keio University Hospital in Tokyo.

In addition to his work in Keio University, Dr. Okamoto contributed a lot to promote the activity of hematopoietic cell transplantation (HCT) in Japan. He has been working for Japan Society for Hematopoietic Cell Transplantation (JSHCT) as a Board member since 2004. In 2012 Dr. Okamoto became the Chairman of the Board Members, JSHCT and continue to lead the Society. He has also been working for Japan Marrow Donor Program (JMDP) as the Chairman of International Committee and the Board member since its establishment in 1992.

In 1999 to 2005, he also served as the Vice President of World Marrow Donor Association (WMDA) and the Chairman of Accreditation Committee. He served as a member of Advisory Committee, CIBMTR from 2012 to 2014. Dr. Okamoto has been leading Asia-Pacific Blood and Marrow Transplantation Group (APBMT) as the Chairman of the Board of Directors. He is also one of the founding members of the Society. Through those activities, Dr. Okamoto has been contributing to not only fostering the activity of HCT in Asia-pacific countries but also collaboration and harmonization of the global activity of HCT.

Shigeru Ko

SHIGERU KO, MD, PhD

SHIGERU KO, MD, PhD

Shigeru Ko, MD, PhD, received his MD degree at Nagoya University School of Medicine in 1992 and his PhD degree for Internal Medicine at Nagoya University Graduate School of Medicine in 1999. He has been seeing patients as a physician for 25 years (specialist of Pancreatology) at several local clinics to University hospitals including Keio University Hospital. He spent 2.5 years in the departament of Physiology, UT Southwestern Medical Center at Dallas, TX as a research fellow from 2000 to 2003. He is currently Project Professor at the Department of Systems Medicine, Keio University School of Medicine. His current field of interest in research is regenerative medicine of the pancreas.

Kokichi Nakasuji

KOKICHI NAKASUJI

KOKICHI NAKASUJI

Kokichi Nakasuji, M.S. (Pharmaceutical Sciences), is currently working as an expert advisor in a patent attorney’s office in Japan. Previously he worked as an intellectual property management advisor in charge of biotechnology and medical science fields for Chiba University (2007-2018) and as a toxicological and molecular biological researcher and a section manager of the intellectual property department for Daiichi Pharmaceutical Co., Ltd. (1975-2007). Additionally, he was a member and a deputy chairperson of Japan Intellectual Property Association, biotechnology committee (1994-2007).

Satoshi Kunitada

SATOSHI KUNITADA, PhD

SATOSHI KUNITADA, PhD

Satoshi Kunitada, PhD, served as the Japanese head of clinical development at Daiichi Sankyo Co. Ltd (2010-2014) and as committee chairman of the Japan Pharmaceutical Manufacturers Association (2016-2020).

Yoshinari Sato

YOSHINARI SATO, PhD

YOSHINARI SATO, PhD

Yoshinari Sato, Ph.D. has worked for Daiichi Pharmaceutical Co., Ltd. (1971 to 2006), and Japan Health Sciences Foundation (2006 to 2012).

Investors and Partners

UTEC

University of Tokyo Edge Capital (UTEC) has conduncted venture capital investments pioneering frontiers to solve global issues of humankind, by bringing capital, talent and knowledge, around science and technology.

SDP

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company based in Japan with the corporate mission “to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.”